View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
WEDNESDAY, Feb. 29 (HealthDay News) -- Amantadine improves the rate of functional recovery during active treatment in patients with severe traumatic brain injury, according to a study published in the March 1 issue of the New England Journal of Medicine.
Joseph T. Giacino, Ph.D., from Harvard Medical School in Boston, and colleagues enrolled 184 patients who were in a vegetative or minimally conscious state four to 16 weeks after traumatic brain injury and who were receiving inpatient rehabilitation. Patients were randomly assigned to receive amantadine or placebo for four weeks and were followed for two weeks after the treatment was discontinued. The Disability Rating Scale (DRS; range, 0 to 29, with higher scores indicating greater disability) was used to assess the rate of functional recovery.
The researchers found that, during the treatment period, recovery was significantly faster in the amantadine group than in the placebo group (difference in slope for DRS score of 0.24 points per week). A prespecified subgroup analysis showed that the treatment effect was similar for patients in a vegetative state and those in a minimally conscious state. The rate of improvement in patients who received amantadine slowed during the two weeks after treatment and was significantly slower than the rate of improvement in patients who received placebo. The overall improvement in DRS scores from baseline to two weeks after discontinuation of treatment was similar between the groups, and there were no significant differences in the incidence of serious adverse events between the groups.
"Amantadine accelerated the pace of functional recovery during active treatment in patients with post-traumatic disorders of consciousness," the authors write.
One of the study authors disclosed financial relationships with pharmaceutical and medical device companies.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top